
M Carrie Miceli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9078216/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell, 2016, 18, 533-540.	11.1	307
2	De Novo Nonsense Mutations in KAT6A, a Lysine Acetyl-Transferase Gene, Cause a Syndrome Including Microcephaly and Global Developmental Delay. American Journal of Human Genetics, 2015, 96, 498-506.	6.2	115
3	Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. Journal of Cell Biology, 2016, 213, 275-288.	5.2	102
4	PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology, 2014, 82, 2085-2091.	1.1	94
5	Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy. Science Translational Medicine, 2012, 4, 164ra160.	12.4	77
6	<i>DMD</i> genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Human Mutation, 2018, 39, 1193-1202.	2.5	65
7	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology, 2017, 89, 1811-1820.	1.1	58
8	A wellâ€ŧolerated core needle muscle biopsy process suitable for children and adults. Muscle and Nerve, 2020, 62, 688-698.	2.2	20
9	Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models. Molecular Therapy - Nucleic Acids, 2019, 18, 580-589.	5.1	15
10	Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse. Molecular Therapy - Nucleic Acids, 2018, 11, 180-191.	5.1	10
11	Selective Phosphorylation of the Dlg1AB Variant Is Critical for TCR-Induced p38 Activation and Induction of Proinflammatory Cytokines in CD8+ T Cells. Journal of Immunology, 2014, 193, 2651-2660.	0.8	7
12	Large in-frame 5′ deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature. Neuromuscular Disorders, 2019, 29, 863-873.	0.6	6
13	Validation and Detection of Exon Skipping Boosters in DMD Patient Cell Models and mdx Mouse. Methods in Molecular Biology, 2018, 1828, 309-326.	0.9	4
14	Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels. Frontiers in Cell and Developmental Biology, 2022, 10, 830415.	3.7	4